Today: Sun 5 Jul 2015
Register & Login:  Register
Register Login

atrial fibrillation

The following articles have the tag atrial fibrillation

NOACs equally effective, but bleeding differs

NOACs equally effective, but bleeding differs

IN ELDERLY patients with atrial fibrillation or venous thromboembolism, novel oral anticoagulants are just as effective as warfarin but have distinct bleeding patterns, a systematic review has found. British researchers analysed data from 30,000 patients aged 75 or older in 19 randomised controlled trials. Major bleeding was significantly less likely with apixaban and there was a non-significant increased risk with dabigatran, when compared with vitamin K antagonists (VKA). Dabigatran caused more gastrointestinal bleeding but less intracranial bleeding than VKA. Apixaban also had a lower risk of intracranial bleeding compared with VKA. Circulation 2015; online 20 ...

Atrial fibrillation: Should we screen?

Atrial fibrillation: Should we screen?

SHOULD all older patients be screened for atrial fibrillation (AF)?

Atrial fibrillation improved by weight loss

Atrial fibrillation improved by weight loss

LONG-TERM sustained weight loss can lead to freedom from atrial fibrillation (AF) in obese patients without the use of drugs or surgical intervention, Australian research shows.

Stroke hotspots in Australia identified

MORE than 51,000 Australians will have a stroke this year and South Australia and Tasmania carry the highest burden of stroke in the country, a report shows.

Asymptomatic AF screening could reduce strokes cost-effectively

OPPORTUNISTIC screening for asymptomatic atrial fibrillation (AF) could be a cost-effective way to reduce the risk of stroke and premature death, research suggests.

$700m payout to dabigatran patients

THE manufacturer of the oral anticoagulant dabigatran (Pradaxa) will pay $700 million to thousands of US patients who filed lawsuits against the company alleging they experienced bleeding while on the drug.

Warfarin preferred option for some: expert

DESPITE increasingly positive safety and efficacy data for new oral anticoagulants (NOACs) and reports of an antidote becoming available in two years, warfarin still has a place in therapy, according to an international expert.

Dabigatran increases gastrointestinal bleed risk: FDA review

THE new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) lowers the risk of intracranial haemorrhage and death compared to warfarin but increases the risk of major gastrointestinal bleeding, according to a major FDA review.

AF screening in pharmacies with iPhone app mooted

AF screening in pharmacies with iPhone app mooted

PHARMACY-based screening for undiagnosed atrial fibrillation (AF) using an iPhone app could help identify thousands of Australians at risk of stroke.

NOAC education and lack of antidote a concern for GPs

GPs say they have not been sufficiently educated about using new oral anticoagulants (NOACs) and 70% say the lack of an antidote is a concern, an MO poll has shown.

Dabigatran PBS listing expected

A SEPTEMBER PBS listing is expected for dabigatran (Pradaxa), more than two years after it was first recommended for reimbursement.

September PBS listing likely for dabigatran

September PBS listing likely for dabigatran

NEW generation antithrombotic dabigatran is expected be listed on the PBS for stroke prevention in September, more than two years after it was first approved for government reimbursement.

Caution with switching warfarin to dabigatran

DOCTORS should exercise caution when changing patients to dabigatran (Pradaxa, Boehringer Ingelheim), an expert has warned, after research found the risks of thrombosis and bleeding were increased in previous warfarin users.

New guide clarifies role of ablation in AF

THE increasing prevalence of atrial fibrillation (AF), together with some confusion about the optimal use of catheter ablation, has prompted the development of Australia’s first consensus statement to guide treatment of AF.

New guide clarifies catheter ablation

CONFUSION about the optimal use of catheter ablation and the increasing prevalence of atrial fibrillation (AF) has prompted the development of Australia’s first consensus statement to guide treatment.

Hyperthyroidism increases AF risk

Hyperthyroidism increases AF risk

PATIENTS with subclinical hyperthyroidism carry an increased risk of developing atrial fibrillation (AF) compared to those with normal thyroid function, a general practice-based study confirms.

Trial results reinforce dabigatran safety in AF

AN FDA safety advisory and new clinical trial results are reassuring and add further weight to calls for Pradaxa (dabigatran) to be PBS listed for atrial fibrillation, experts say.

Little impact made on stroke burden: study

DESPITE improved treatment of atrial fibrillation (AF), there is little evidence any impact has been made on stroke burden, a study suggests.

Subclinical hyperthyroidism increases risk of AF

SUBCLINICAL hyperthyroidism (SCH) is associated with a raised risk of incident atrial fibrillation (AF) and with death from coronary heart disease (CHD), a study suggests.

AF without stroke raises risk of dementia

EVEN without a stroke, atrial fibrillation (AF) raises the risk of cognitive and functional decline, according to an analysis of two randomised controlled trials of treatments to reduce cardiovascular disease.

AT LEAST 50,000 Australians aged 40 years or more may have atrial fibrillation (AF) without knowing it

Many over-40s living with undiagnosed AF time bomb

AT LEAST 50,000 Australians aged 40 years or more may have atrial fibrillation (AF) without knowing it, new data suggest.

Dismay at drug company push for govt subsidy

A DRUG company push to enlist doctors and patients into pressuring the federal government to subsidise the warfarin alternative dabigatran has been branded “appalling” and “inappropriate”.

Modelling shows dabigatran benefit

MODELLING suggests the anticoagulant dabigatran offers a positive benefit compared to warfarin in the management of non-valvular atrial fibrillation (AF), researchers say.

Anticoagulant under-prescribing may raise stroke risk in AF

MORTALITY rates from stroke in patients with atrial fibrillation (AF) are excessively high and a contributing factor may be the under-prescribing of anticoagulants, Australian experts say. Researchers from the University of New South Wales (UNSW) and the Ingham Institute looked at nearly 27,000 cases of ischaemic stroke occurring between 2000 and 2006 in the Program of Research Informing Stroke Management (PRISM) study, and found that a quarter were due to atrial fibrillation (AF). Patients with AF were twice as likely to die in hospital and had mortality rates of nearly 40% ...

Concern over drug familiarisation programs for patients

EXPERTS in ethics and quality use of medicines have voiced concern over the continued use of patient familiarisation programs, suggesting they are more about pitching to consumers than good clinical practice. The comments follow last week's announcement by Boehringer Ingelheim that doctors will be able to enrol their atrial fibrillation patients in a program that will see them receive free dabigatran (Pradaxa). The national product familiarisation program (PFP) will allow doctors to enrol up to 10 patients to receive the drug - ahead of any PBS listing. Professor Paul Komesaroff, chair of the ethics committee at ...

Dabigatran approved for initial PBS listing

THE oral thrombin inhibitor dabigatran has been approved for listing on the PBS for use in patients with atrial fibrillation (AF) under a new pilot, fast-track regulatory process. Dabigatran (Pradaxa) reimbursement was approved at the March meeting of the Pharmaceutical Benefits Advisory Committee (PBAC) for use in patients with AF at risk of stroke on the basis of “acceptable cost-effectiveness”. However, TGA approval was granted only today, a Health Department spokesperson confirmed. Dabigatran was one of a number of drugs approved as part of a pilot run by the department, allowing for expedited reimbursement review, a spokesman ...

Strong family ties linked to the development of AF

Patients with any first-degree relative with atrial fibrillation (AF) have a significantly increased risk of developing the condition themselves, independently of traditional AF risk factors, experts say.  Results from a US community-based prospective study of 4421 people free of AF at baseline show that those with a first-degree relative with AF had a 40% greater risk of developing AF themselves during an eight year follow-up. This increased risk was not attenuated after adjusting for age, sex, BMI, blood pressure, treatment for hypertension, heart murmur and heart failure, or having any of the four common AF-related genetic variants. ...

The rising rate of AF

A decade ago, atrial fibrillation was considered an emerging epidemic – has it now reached its peak? Kate Woods looks at the rise and rise of AF.

High cost of atrial fibrillation needs greater public awareness

A NEW report has highlighted the need for public awareness campaigns to improve knowledge of atrial fibrillation (AF), which experts say is under-diagnosed and often inadequately managed. The Economic Costs of Atrial Fibrillation in Australia report, prepared on behalf of the National Stroke Foundation, revealed AF costs the Australian health system more than $1.2 billion annually based on related hospitalisations, strokes, cardiovascular events and loss of productivity. According to the report, patients with AF had a seven times greater risk of stroke compared to the general population, and a three- times greater risk of heart failure. ...

Serious risks of AF are widely misunderstood

MAJOR gaps exist in the knowledge of the cardiovascular risks associated with atrial fibrillation (AF), according to a recent international study which found that both patients and cardiologists may underestimate the seriousness of the condition.  A survey of more than 1600 cardiologists and patients with AF in 11 countries, including Australia, revealed only 43% of cardiologists and 55% of patients considered AF to be life-threatening, despite the condition doubling the risk of death, and having a five times greater risk of stroke.   Cardiologists also underestimated their patient’s understanding of the benefits of AF treatments and overestimated ...